HK1224334A1 - 誘導抗腫瘤免疫力的化合物及其用途 - Google Patents

誘導抗腫瘤免疫力的化合物及其用途

Info

Publication number
HK1224334A1
HK1224334A1 HK16112613.4A HK16112613A HK1224334A1 HK 1224334 A1 HK1224334 A1 HK 1224334A1 HK 16112613 A HK16112613 A HK 16112613A HK 1224334 A1 HK1224334 A1 HK 1224334A1
Authority
HK
Hong Kong
Prior art keywords
compounds
methods
tumor immunity
inducing anti
inducing
Prior art date
Application number
HK16112613.4A
Other languages
English (en)
Inventor
R Cubillos-Ruiz Juan
H Glimcher Laurie
Original Assignee
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell filed Critical Univ Cornell
Publication of HK1224334A1 publication Critical patent/HK1224334A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16112613.4A 2013-09-25 2016-11-02 誘導抗腫瘤免疫力的化合物及其用途 HK1224334A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361882461P 2013-09-25 2013-09-25
PCT/US2014/057525 WO2015048331A1 (en) 2013-09-25 2014-09-25 Compounds for inducing anti-tumor immunity and methods thereof

Publications (1)

Publication Number Publication Date
HK1224334A1 true HK1224334A1 (zh) 2017-08-18

Family

ID=51662378

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16112613.4A HK1224334A1 (zh) 2013-09-25 2016-11-02 誘導抗腫瘤免疫力的化合物及其用途

Country Status (6)

Country Link
US (3) US9957506B2 (zh)
EP (2) EP3049521B1 (zh)
DK (1) DK3049521T3 (zh)
ES (1) ES2724300T3 (zh)
HK (1) HK1224334A1 (zh)
WO (1) WO2015048331A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
US20150018406A1 (en) 2012-03-09 2015-01-15 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
US9957506B2 (en) 2013-09-25 2018-05-01 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
CN112107693B (zh) 2013-12-03 2023-05-26 西北大学 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途
EP3164113B1 (en) 2014-06-04 2019-03-27 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016134104A1 (en) * 2015-02-18 2016-08-25 Exicure, Inc. Immuno-regulatory lipid containing spherical nucleic acids
AU2016341131A1 (en) 2015-10-19 2018-05-10 University Of Massachusetts Anti-cancer and anti-inflammatory therapeutics and methods thereof
US20180059115A1 (en) * 2016-08-05 2018-03-01 The Wistar Institute Of Anatomy And Biology Methods for monitoring polymorphonuclear myeloid derived suppressor cells, and compositions and methods of treatment of cancer
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018067813A1 (en) * 2016-10-05 2018-04-12 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and systems for augmenting immune system responses
WO2018102655A1 (en) * 2016-12-02 2018-06-07 Glimcher Laurie H Ascites based methods
WO2018102751A1 (en) 2016-12-02 2018-06-07 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
US20180346446A1 (en) 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
US10392367B2 (en) 2017-06-01 2019-08-27 Quentis Therapeutics, Inc. IRE1 small molecule inhibitors
WO2018226685A2 (en) * 2017-06-06 2018-12-13 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways
KR20200028997A (ko) 2017-07-13 2020-03-17 노오쓰웨스턴 유니버시티 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법
US20230026844A1 (en) * 2019-12-12 2023-01-26 University Of Maryland, Baltimore Inhibitors of Cancer Biomarkers and Uses Thereof
WO2021173847A1 (en) * 2020-02-27 2021-09-02 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Cobra1/nelf-b as a booster for efficacy of cd8+ t cell-based therapy
US20230181543A1 (en) * 2020-02-28 2023-06-15 The Wistar Institute Of Anatomy And Biology Treatment of carm1-overexpressing and/or arid1a mutant cancers with ire-1/xbp-1 inhibitors
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
CN113546045B (zh) * 2021-08-18 2022-11-11 浙江大学 恢复肿瘤微环境失活树突状细胞功能的纳米制剂及应用
CN113817677B (zh) * 2021-09-29 2023-08-18 四川大学 泛酸或其衍生物与α-D-葡萄糖-1,6-二磷酸或其衍生物在促进DC迁移中的用途
CN115040663B (zh) * 2022-06-15 2023-12-12 上海交通大学医学院附属仁济医院 溶质载体家族38成员2在制备多发性骨髓瘤治疗药物中的应用

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3249651C2 (de) 1982-12-24 1989-03-30 Tartuskii Gu Raummodell einer molek}lstruktur
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4740468A (en) 1985-02-14 1988-04-26 Syntex (U.S.A.) Inc. Concentrating immunochemical test device and method
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
ATE68013T1 (de) 1985-07-05 1991-10-15 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
DE3851153T2 (de) 1987-12-11 1995-01-05 Hughes Howard Med Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US4879214A (en) 1988-11-15 1989-11-07 E. I. Du Pont De Nemours And Company Differentiation of nucleic acid segments on the basis of nucleotide differences
US4906122A (en) 1988-11-28 1990-03-06 Barrett Edward J Coupling for molecular models
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5019512A (en) 1989-03-17 1991-05-28 Baxter International Inc. Spin filter for removing substantially cell-free culture medium from suspension cell culture system
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ATE423195T1 (de) 1989-07-25 2009-03-15 Cell Genesys Inc Homologe rekombination für universelle donorzellen und chimerische säugetierzellen
CA2002536C (en) 1989-11-08 1996-02-20 Peter H. Buist Dynamic molecular model
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE163046T1 (de) 1990-10-31 1998-02-15 Somatix Therapy Corp Genetische veränderung von endothelzellen
ATE121129T1 (de) 1990-11-14 1995-04-15 Procter & Gamble Verfahren zur herstellung von sauerstoff- bleichsysteme enthaltende phosphatfreie geschirrspülmittelzusammensetzungen.
CA2105300C (en) 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
JPH07509694A (ja) 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
DE69334095T2 (de) 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
AU682156B2 (en) 1992-10-15 1997-09-25 Dana-Farber Cancer Institute, Inc. Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-alpha function
EP0672131B1 (en) 1992-10-30 2003-12-17 The General Hospital Corporation A novel cell cycle control protein
US5547835A (en) 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
PL310327A1 (en) 1993-02-12 1995-12-11 Univ Leland Stanford Junior Adjustable transcription of target genes and other biological processes
DE705334T1 (de) 1993-06-14 1999-12-30 Basf Ag Strenge kontrolle der genexpression in eukaryotischen zellen durch auf tetrazyklin ansprechende promotoren
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
WO1995003832A1 (en) 1993-07-30 1995-02-09 Thomas Jefferson University Intracellular immunization
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US5583973A (en) 1993-09-17 1996-12-10 Trustees Of Boston University Molecular modeling method and system
US5840832A (en) 1994-10-21 1998-11-24 The Johns Hopkins University Transcription factor regulating MHC expression, CDNA and genomic clones encoding same and retroviral expression constructs thereof
ATE211506T1 (de) 1995-01-31 2002-01-15 Bioimage As Ein verfahren zum nachweis biologisch aktiver substanzen
US5612894A (en) 1995-02-08 1997-03-18 Wertz; David H. System and method for molecular modeling utilizing a sensitivity factor
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
WO1997010333A1 (fr) 1995-09-14 1997-03-20 Sumitomo Electric Industries, Ltd. Nouvelles proteines s'exprimant specifiquement dans le cancer du foie, genes codant ces proteines, anticorps actifs contre ces proteines et procede de detection de l'expression de ces proteines
US6413735B1 (en) 1996-03-15 2002-07-02 Munin Corporation Method of screening for a modulator of angiogenesis
WO1997039721A2 (en) 1996-04-23 1997-10-30 President And Fellows Of Harvard College Methods and compositions for regulating t cell subsets by modulating transcription factor activity
US6093573A (en) 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US5972995A (en) 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
US7718694B2 (en) 1997-10-16 2010-05-18 Children's Hospital & Research Center At Oakland Compositions and methods for therapy for diseases characterized by defective chloride transport
US5945307A (en) 1998-01-26 1999-08-31 Millennium Pharmaceuticals, Inc. Isolated nucleic acid molecules encoding a G-protein coupled receptor showing homology to the 5HT family of receptors
US6388788B1 (en) 1998-03-16 2002-05-14 Praelux, Inc. Method and apparatus for screening chemical compounds
US6080576A (en) 1998-03-27 2000-06-27 Lexicon Genetics Incorporated Vectors for gene trapping and gene activation
US6037148A (en) 1998-09-29 2000-03-14 Millennium Pharmaceuticals, Inc. MTBX protein and nucleic acid molecules and uses therefor
US7439061B2 (en) 1998-07-21 2008-10-21 The Regents Of The University Of Michigan DNA encoding the novel mammalian protein, Ire1p
US6630312B2 (en) 1999-08-10 2003-10-07 Joslin Diabetes Center, Inc. Method for identifying compounds for treatment of insulin resistance
AU1075701A (en) 1999-10-08 2001-04-23 Protogene Laboratories, Inc. Method and apparatus for performing large numbers of reactions using array assembly
DE60034817T2 (de) 1999-12-30 2008-01-31 President And Fellows Of Harvard College, Cambridge Verfahren zur modulierung der aktivität von th2-zellen durch modulierung der aktivität von xbp-1
EP1266018B1 (en) 2000-03-24 2008-05-07 Genencor International, Inc. Production of secreted proteins by recombinant eukaryotic cells
EP1390052A4 (en) 2001-04-24 2008-10-08 Harvard College INHIBITION OF JUN KINASE
US7306905B2 (en) 2001-05-18 2007-12-11 New York University Method of identifying substances useful for promoting resistance to cell stress
US20040077020A1 (en) 2001-11-30 2004-04-22 Mannick Elizabeth E. Diagnostic microarray for inflammatory bowel disease, crohn's disease and ulcerative colitis
US7666587B2 (en) 2002-04-12 2010-02-23 New York University Method of screening test substances for treating or preventing a disease mediated by plasma cells
AU2003234198A1 (en) 2002-04-22 2003-11-03 University Of Michigan Novel genes, compositions, and methods for modulating the unfolded protein response
WO2003090685A2 (en) 2002-04-24 2003-11-06 The Regents Of The University Of California Methods for stimulating tlr/irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses
US7220539B1 (en) 2002-06-12 2007-05-22 The Salk Institute For Biological Studies Protein kinase B/Akt modulators and methods for the use thereof
US20040170622A1 (en) 2002-08-30 2004-09-02 President And Fellows Of Harvard College Methods and compositions for modulating XBP-1 activity
WO2004037373A2 (en) 2002-10-21 2004-05-06 The Scripps Research Institute CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF β-GLUCOSIDASE
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
EP1657311A4 (en) 2003-07-11 2006-10-11 Banyu Pharma Co Ltd METHOD OF EVALUATING COMPOUND EFFECTIVE IN THE TREATMENT OF OBESITY
WO2005034737A2 (en) 2003-10-09 2005-04-21 University Of Massachusetts Methods for diagnosing and treating endoplasmic reticulum (er) stress diseases
DE10361944A1 (de) 2003-12-31 2005-07-28 Viromics Gmbh Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung
WO2005077048A2 (en) 2004-02-09 2005-08-25 The Johns Hopkins University Immune modulation by regulating expression of the “minor” gene in immune dendritic cells
CA2580370A1 (en) 2004-09-15 2006-03-23 Gokhan S. Hotamisligil Reducing er stress in the treatment of obesity and diabetes
WO2006031930A2 (en) 2004-09-15 2006-03-23 The President And Fellows Of Harvard College Modulation of xbp-1 activity for treatment of metabolic disorders
US20060073213A1 (en) 2004-09-15 2006-04-06 Hotamisligil Gokhan S Reducing ER stress in the treatment of obesity and diabetes
US20060063187A1 (en) 2004-09-15 2006-03-23 Hotamisligil Gokhan S Modulation of XBP-1 activity for treatment of metabolic disorders
US8273700B2 (en) 2005-09-29 2012-09-25 The Johns Hopkins University Methods and compositions for treatment of cystic fibrosis
EP1954254A4 (en) 2005-11-01 2010-12-22 Harvard College MODULATION OF ENDOPLASMIC RETICULUM STRESS IN THE TREATMENT OF TUBEROUS SCLEROSIS
AU2007220039A1 (en) * 2006-02-27 2007-09-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of the unfolded protein response and methods for their use
WO2008039445A2 (en) 2006-09-25 2008-04-03 President And Fellows Of Harvard College Polymorphisms in the human xbp-1 gene are associated with inflammatory bowel disease
CN101301478A (zh) 2007-05-10 2008-11-12 贝勒医学院 以低氧诱导因子1-α(HIF1α)作为靶标的G-四合体寡核苷酸
WO2008143876A2 (en) 2007-05-14 2008-11-27 The Trustees Of Columia University In The City Of New York Agents and assays for modulating neurodegeneration
CN102015606B (zh) 2007-06-08 2015-02-04 满康德股份有限公司 IRE-1α抑制剂
US8940479B2 (en) 2008-01-14 2015-01-27 Cornell University Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity
US7875711B2 (en) 2008-04-17 2011-01-25 Alnylam Pharamaceuticals, Inc. Compositions and methods for inhibiting expression of XBP-1 gene
WO2010008860A1 (en) 2008-06-23 2010-01-21 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
WO2010014905A2 (en) 2008-07-31 2010-02-04 President And Fellows Of Harvard College Polymorphisms associated with inflammatory bowel disease
CN104230901A (zh) 2008-09-15 2014-12-24 加利福尼亚大学董事会 用于调节ire1、src和abl活性的方法和组合物
CA2749947A1 (en) * 2009-01-30 2010-08-05 Bayer Healthcare Llc Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition
US20100266618A1 (en) * 2009-03-18 2010-10-21 Children's Hospital Of Eastern Ontario Research Institute Compositions and methods for augmenting activity of oncolytic viruses
WO2010141619A1 (en) 2009-06-02 2010-12-09 President And Fellows Of Harvard College Methods for modulating toll-like receptor mediated activation of cells of the innate immune system by modulating xbp-1 activity
WO2010151827A1 (en) 2009-06-25 2010-12-29 Bayer Healthcare Llc X-box binding proteins (xbp-1) variants and methods of using the same
WO2011022316A1 (en) 2009-08-20 2011-02-24 The Regents Of The University Of Colorado, A Body Corporate Mirnas dysregulated in triple-negative breast cancer
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
ES2782357T3 (es) 2009-11-03 2020-09-14 Fosun Orinove Pharmatech Inc Inhibidores de IRE 1 alfa
US8434740B2 (en) 2010-08-30 2013-05-07 Marinus R. Logtenberg Apparatus (sheave) for guiding cable in and out of manholes and conduits
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
WO2012138715A2 (en) 2011-04-04 2012-10-11 Georgetown University Small molecule inhibitors of xbp1 splicing
US20150018406A1 (en) 2012-03-09 2015-01-15 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
WO2013142571A2 (en) 2012-03-20 2013-09-26 Cornell University Assays for the identification of compounds that modulate lipid homeostasis
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US20140170622A1 (en) 2012-09-11 2014-06-19 John J. Pastrick Training Pad Connector
US10323013B2 (en) * 2013-04-23 2019-06-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof
US9957506B2 (en) 2013-09-25 2018-05-01 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
US10450566B2 (en) 2019-10-22
ES2724300T3 (es) 2019-09-10
EP3521431A1 (en) 2019-08-07
EP3049521B1 (en) 2019-03-06
US9957506B2 (en) 2018-05-01
US20180201933A1 (en) 2018-07-19
US20180258426A1 (en) 2018-09-13
EP3049521A1 (en) 2016-08-03
WO2015048331A1 (en) 2015-04-02
DK3049521T3 (en) 2019-04-23
US10421965B2 (en) 2019-09-24
US20160237429A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
HK1224334A1 (zh) 誘導抗腫瘤免疫力的化合物及其用途
PL3116350T3 (pl) Poduszka podróżna
GB201302789D0 (en) Apparatus
HK1224172A1 (zh) 用於誘導軟骨形成的化合物和方法
GB2501987B (en) Jarring apparatus
GB201300928D0 (en) Apparatus
GB201323121D0 (en) Downhole Apparatus
GB201406414D0 (en) Downhole Apparatus
PL3079743T3 (pl) Urządzenie
EP2960025A4 (en) RETAINING DEVICE
GB201416857D0 (en) Fall prevention apparatus
PL2976209T3 (pl) Urządzenie do tłoczenia folii
GB201312517D0 (en) Apparatus
SG10201706220TA (en) Adjustable fracturing system
GB201320855D0 (en) Apparatus
HK1173029A2 (en) Fastening apparatus
GB201318020D0 (en) Drilling apparatus
GB201304801D0 (en) Downhole apparatus
GB201323127D0 (en) Downhole apparatus
GB2500109B (en) Downhole Apparatus
GB201319954D0 (en) Apparatus
GB201311738D0 (en) Apparatus
GB201310529D0 (en) Traysealing apparatus
GB2516017B (en) Solar-powered apparatus
GB2505976B (en) Apparatus

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230927